Annovis Bio Files 8-K for Financials and Exhibits

Ticker: ANVS · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1477845

Annovis Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyAnnovis Bio, Inc. (ANVS)
Form Type8-K
Filed DateSep 30, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, exhibits

Related Tickers: ANVS

TL;DR

Annovis Bio (ANVS) filed an 8-K on 9/30/24 for financials. Check it out.

AI Summary

Annovis Bio, Inc. filed an 8-K on September 30, 2024, reporting on financial statements and exhibits. The company, previously known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA.

Why It Matters

This filing provides an update on Annovis Bio's financial status and exhibits, which are crucial for investors to assess the company's performance and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

  • Annovis Bio, Inc. (company) — Registrant
  • QR Pharma, Inc. (company) — Former company name
  • September 30, 2024 (date) — Date of report
  • Malvern, PA (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on financial statements and exhibits as of September 30, 2024.

What was Annovis Bio, Inc.'s former company name?

Annovis Bio, Inc.'s former company name was QR Pharma, Inc.

In which state is Annovis Bio, Inc. incorporated?

Annovis Bio, Inc. is incorporated in Delaware.

What is the address of Annovis Bio, Inc.'s principal executive offices?

The address of Annovis Bio, Inc.'s principal executive offices is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.

What is the Commission File Number for Annovis Bio, Inc.?

The Commission File Number for Annovis Bio, Inc. is 001-39202.

Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-09-30 08:38:31

Key Financial Figures

  • $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: September 30, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.